Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 97202

4 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
July 09, 2025
Product types
Drug
Classifications
Class II and Class III
Statuses
Ongoing
Recalling firm wording
Boothwyn Pharmacy LLC

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

4 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 4

Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy

D-0606-2025
Recall number
D-0606-2025
Initiated
July 09, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Boothwyn Pharmacy LLC
Quantity
642 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug

Code information

03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025

Distribution pattern

U.S. Nationwide

drug · product 2 of 4

Fluorescein 2% Ophth, 3 ML, Boothwyn Pharmacy, 800-476-7496

D-0607-2025
Recall number
D-0607-2025
Initiated
July 09, 2025
Classification
Class III
Status
Ongoing
Recalling firm
Boothwyn Pharmacy LLC
Quantity
8 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug

Code information

06092025@23 BUD 09/09/2025

Distribution pattern

U.S. Nationwide

drug · product 3 of 4

Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy

D-0608-2025
Recall number
D-0608-2025
Initiated
July 09, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Boothwyn Pharmacy LLC
Quantity
186 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug

Code information

03202025@9 BUD 07/18/2025

Distribution pattern

U.S. Nationwide

drug · product 4 of 4

Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy

D-0609-2025
Recall number
D-0609-2025
Initiated
July 09, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Boothwyn Pharmacy LLC
Quantity
648 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug

Code information

03202025@2, 03202025@3 and 03202025@4 BUD 07/18/2025

Distribution pattern

U.S. Nationwide